Skip Navigation

European Heart Journal 2002 23(20):1604-1608; doi:10.1053/euhj.2002.3312
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chung, N.A.Y.
Right arrow Articles by Lip, G.Y.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chung, N.A.Y.
Right arrow Articles by Lip, G.Y.H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Angiogenesis in myocardial infarction. An acute or chronic process?

N.A.Y. Chung, C. Lydakis, F. Belgore, A.D. Blann and G.Y.H. Lipf1

Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, U.K.

revised May 12, 2002; accepted May 22, 2002

Abstract

Background In the acute phase of myocardial infarction (acute MI) marked endothelial damage occurs within the first 24h following thrombolysis with streptokinase. We investigated whether this is associated with a change in levels of vascular endothelial growth factor (VEGF, possibly marking angiogenesis) in the first 24h post thrombolysis compared to chronic MI patients (defined as MI>3 months previously).

Methods We recruited 15 patients (nine male, mean age 59±SD 10 years) with first-presentation acute MI, who were given 1·5 million U streptokinase over 1h and aspirin 300mg orally as standard treatment. Plasma samples were taken prior to the start of thrombolysis, followed every 15min for 1h, at 3h and finally at 24h post-thrombolysis. Baseline levels of measured indices in the acute MI patients were compared to two control groups: (i) 26 chronic MI patients (18 male, mean age 59·9±7·0 years); and (ii) 26 apparently healthy controls (17 male, mean age 59·6±14·1 years). Plasma VEGF and the soluble form of its receptor Flt-1 (sFlt-1) were measured by ELISA.

Results Plasma levels of VEGF were significantly higher in patients with a history of chronic MI compared to patients with acute MI (P=0·007) and healthy controls (P=0·002) with similar levels between acute MI patients and healthy controls (P=0·755). Levels of sFlt-1 in the acute (P=0·013) and chronic (P<0·001) MI groups were lower compared to healthy controls. In the first 24h post-thrombolysis in the acute MI group, levels of sFlt-1 changed significantly (P=0·039), but there was no change in levels of VEGF (P=0·207).

Conclusion In the first 24h of acute MI, significant changes in levels of VEGF receptor sFlt-1, but not VEGF, are seen. Plasma VEGF and sFlt-1 levels are markedly changed in chronic MI patients, suggesting that the activation of angiogenesis in MI patients may be a delayed response. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

Key Words: Angiogenesis, vascular endothelial growth (VEGF), soluble Flt-1, myocardial infarction (MI)

f1 Correspondence: Professor G. Y. H. Lip, Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, U.K.

References

  1. Lip GYH, Lydakis C, Nuttall SL, Landray MJ, Watson RD, Blann AD. A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction. J Intern Med. 2000;248:316–318[CrossRef][ISI][Medline]
  2. Lip GYH, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res. 1997;34:255–265[Abstract/Free Full Text]
  3. Janssen JH, Nilsson TK, Johnson O. von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart. 1998;80:334–337[Abstract/Free Full Text]
  4. Blann AD, Waite MA. von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Coron Artery Dis. 1996;7:143–147[ISI][Medline]
  5. Blann AD, McCollum CN. von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinolysis. 1999;10:375–380[ISI][Medline]
  6. Barger AC, Beeuwkes R III, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med. 1984;310:175–177[ISI][Medline]
  7. Inoue M, Itoh H, Ueda M. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 1998;98:2108–2116[Abstract/Free Full Text]
  8. Kamat BR, Galli SJ, Barger AC, Lainey LL, Silverman KJ. Neovascularization and coronary atherosclerotic plaque: cinematographic localization and quantitative histologic analysis. Human Pathol. 1987;18:1036–1042[ISI][Medline]
  9. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126[Free Full Text]
  10. Sueishi K, Yonemitsu Y, Nakagawea K, Kaneda Y, Kumamoto M, Nakashima Y. Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. Ann NY Acad Sci. 1997;811:311–322[Free Full Text]
  11. Chen YX, Nakashima Y, Tanaka K, Shiraishi S, Nakagawa K, Sueishi K. Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries. Arterioscler Thromb Vasc Biol. 1999;19:131–139[Abstract/Free Full Text]
  12. Blann, AD, Belgore, FM, McCollom, CN, Silverman, S, Lip, PL, Lip, GYH, Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes, Clin Sci, 101
  13. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res. 1994;28:1176–1179[Abstract/Free Full Text]
  14. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 1994;90:649–652[Abstract/Free Full Text]
  15. Ladoux A, Frelin C. Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem Biophys Res Commun. 1993;195:1005–1010[CrossRef][ISI][Medline]
  16. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem. 1995;270:13333–13340[Abstract/Free Full Text]
  17. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol. 2001;33:409–420[CrossRef][ISI][Medline]
  18. Belgore FM, Blann AD, Lip GY. Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays. Clin Sci (Lond). 2001;100:567–575[Medline]
  19. Hojo Y, Ikeda U, Zhu Y. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol. 2000;35:968–973[Abstract/Free Full Text]
  20. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med. 2000;342:626–633[Abstract/Free Full Text]
  21. Seko Y, Imai Y, Suzuki S. Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy. Clin Sci (Colch). 1997;92:453–454[Medline]
  22. Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N. Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology. 2000;93:168–174[CrossRef][ISI][Medline]
  23. de L, Morrow DA, Gibson CM. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol. 1915;88:353–358
  24. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem. 2001;47:617–623[Abstract/Free Full Text]
  25. Webb NJ, Bottomly MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurements of circulating VEGF levels in clinical disease. Clin Sci (Colch). 1998;94:395–404[Medline]
  26. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995;73:333–346[ISI][Medline]
  27. Kranz A, Rau C, Kochs M, Waltenberger J. Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance. J Mol Cell Cardiol. 2000;32:65–72[CrossRef][ISI][Medline]
  28. Kendall RL, Thomas KA. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993;90:10705–10709[Abstract/Free Full Text]
  29. Goldman CK, Kendall RL, Cabbera G. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumour growth, metastasis and mortality rate. Proc Natl Acad Sci USA. 1998;95:8795–8800[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
Y. Kodama, Y. Kitta, T. Nakamura, H. Takano, K. Umetani, D. Fujioka, Y. Saito, K.-i. Kawabata, J.-e. Obata, A. Mende, et al.
Atorvastatin Increases Plasma Soluble Fms-Like Tyrosine Kinase-1 and Decreases Vascular Endothelial Growth Factor and Placental Growth Factor in Association With Improvement of Ventricular Function in Acute Myocardial Infarction
J. Am. Coll. Cardiol., July 4, 2006; 48(1): 43 - 50.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. W. Lee, G. Y.H. Lip, and A. D. Blann
Plasma Angiopoietin-1, Angiopoietin-2, Angiopoietin Receptor Tie-2, and Vascular Endothelial Growth Factor Levels in Acute Coronary Syndromes
Circulation, October 19, 2004; 110(16): 2355 - 2360.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G. S. Werner, E. Jandt, A. Krack, G. Schwarz, O. Mutschke, F. Kuethe, M. Ferrari, and H. R. Figulla
Growth Factors in the Collateral Circulation of Chronic Total Coronary Occlusions: Relation to Duration of Occlusion and Collateral Function
Circulation, October 5, 2004; 110(14): 1940 - 1945.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chung, N.A.Y.
Right arrow Articles by Lip, G.Y.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chung, N.A.Y.
Right arrow Articles by Lip, G.Y.H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?